All 1 tracked stories fall under one category: clinical-trial. American Brain Tumor Association is most often covered alongside Dr. Annick Desjardins, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention American Brain Tumor Association, all published on July 25, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about American Brain Tumor Association
All 1 tracked stories fall under one category: clinical-trial. American Brain Tumor Association is most often covered alongside Dr. Annick Desjardins, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention American Brain Tumor Association, all published on July 25, 2026. Each carries 5 original sources on average.
Stories tracked
1
Sources per story
5
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 15 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering American Brain Tumor Association. Shared-story counts are live from our verified record — not editorial picks.
Annual glioblastoma diagnoses exceed 12,000 with a grim sub-two-year life expectancy, spotlighting a high-priority target for biotech investment and therapeutic innovation. Dr. Annick Desjardins' awareness messaging underscores the rapid proliferation and clinical chaos that keep this disease among oncology’s toughest nuts to crack.
American Brain Tumor Association is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.